SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER

被引：1
|
作者：
Sakaguchi, Haruna [1 ]
Ishihara, Mikiya [1 ]
Sawaki, Akihiko [1 ]
Nagaharu, Keiki [1 ]
Oda, Hiroyasu [1 ]
Sugawara, Yumiko [1 ]
Tamaru, Satoshi [1 ]
Yamashita, Yoshiki [1 ]
Mizuno, Toshiro [1 ]
Katayama, Naoyuki [1 ]
机构：
[1] Mie Univ Hosp, Dept Hematol & Oncol, Tsu, Mie, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu436.78
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-4-2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer
    Ishihara, M.
    Tamaru, S.
    Oda, H.
    Yamashita, Y.
    Tono, Y.
    Mizuno, T.
    Katayama, N.
    [J]. CANCER RESEARCH, 2016, 76
  • [2] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [3] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [4] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    [J]. BMC CANCER, 2021, 21 (01)
  • [5] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Luai S. Al Rabadi
    Madeline M. Cook
    Andy J. Kaempf
    Megan M. Saraceni
    Michael A. Savin
    Zahi I. Mitri
    [J]. BMC Cancer, 21
  • [6] Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
    Tono, Yasutaka
    Ishihara, Mikiya
    Miyahara, Yoshihiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Shiraishi, Taizo
    Mizuno, Toshiro
    Katayama, Naoyuki
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Stephanie Gu
    Stephen Dusza
    Elizabeth Quigley
    Helen Haliasos
    Alina Markova
    Michael Marchetti
    Andrea P. Moy
    Chau Dang
    Shanu Modi
    Diana Lake
    Sarah Noor
    Mario E. Lacouture
    [J]. Breast Cancer Research and Treatment, 2024, 203 : 271 - 280
  • [8] Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03
    Yamashita, Toshinari
    Kawaguchi, Hidetoshi
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] DESTINY-Breast01 trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
    Jackson, Emily B.
    Simmons, Christine E.
    Gelmon, Karen A.
    [J]. TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
  • [10] Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Chunze Li
    Bei Wang
    Shang-Chiung Chen
    Russell Wada
    Dan Lu
    Xin Wang
    Daniel Polhamus
    Jonathan French
    Shweta Vadhavkar
    Alexander Strasak
    Melanie Smitt
    Amita Joshi
    Meghna Samant
    Angelica Quartino
    Jin Jin
    Sandhya Girish
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 1079 - 1090
12345